Literature DB >> 17974913

Malignant astrocytic glioma: genetics, biology, and paths to treatment.

Frank B Furnari1, Tim Fenton, Robert M Bachoo, Akitake Mukasa, Jayne M Stommel, Alexander Stegh, William C Hahn, Keith L Ligon, David N Louis, Cameron Brennan, Lynda Chin, Ronald A DePinho, Webster K Cavenee.   

Abstract

Malignant astrocytic gliomas such as glioblastoma are the most common and lethal intracranial tumors. These cancers exhibit a relentless malignant progression characterized by widespread invasion throughout the brain, resistance to traditional and newer targeted therapeutic approaches, destruction of normal brain tissue, and certain death. The recent confluence of advances in stem cell biology, cell signaling, genome and computational science and genetic model systems have revolutionized our understanding of the mechanisms underlying the genetics, biology and clinical behavior of glioblastoma. This progress is fueling new opportunities for understanding the fundamental basis for development of this devastating disease and also novel therapies that, for the first time, portend meaningful clinical responses.

Entities:  

Mesh:

Year:  2007        PMID: 17974913     DOI: 10.1101/gad.1596707

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  990 in total

1.  Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity.

Authors:  Youngmi Kim; Eunhee Kim; Qiulian Wu; Olga Guryanova; Masahiro Hitomi; Justin D Lathia; David Serwanski; Andrew E Sloan; Robert J Weil; Jeongwu Lee; Akiko Nishiyama; Shideng Bao; Anita B Hjelmeland; Jeremy N Rich
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 2.  Potential therapeutic implications of cancer stem cells in glioblastoma.

Authors:  Lin Cheng; Shideng Bao; Jeremy N Rich
Journal:  Biochem Pharmacol       Date:  2010-05-10       Impact factor: 5.858

3.  Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies.

Authors:  Demirkan B Gürsel; Yvette S Connell-Albert; Robert G Tuskan; Theonie Anastassiadis; Jessica C Walrath; Jessica J Hawes; Jessica C Amlin-Van Schaick; Karlyne M Reilly
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

4.  JLK1486, a Bis 8-Hydroxyquinoline-Substituted Benzylamine, Displays Cytostatic Effects in Experimental Gliomas through MyT1 and STAT1 Activation and, to a Lesser Extent, PPARγ Activation.

Authors:  Céline Bruyère; Sébastien Madonna; Gwendoline Van Goietsenoven; Véronique Mathieu; Jean Dessolin; Jean-Louis Kraus; Florence Lefranc; Robert Kiss
Journal:  Transl Oncol       Date:  2011-06-01       Impact factor: 4.243

5.  PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.

Authors:  Brian McEllin; Cristel V Camacho; Bipasha Mukherjee; Brandon Hahm; Nozomi Tomimatsu; Robert M Bachoo; Sandeep Burma
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

6.  An NF-κB p65-cIAP2 link is necessary for mediating resistance to TNF-α induced cell death in gliomas.

Authors:  Xueyan Zhao; Travis Laver; Suk W Hong; George B Twitty; Annelies Devos; Marijke Devos; Etty N Benveniste; Susan E Nozell
Journal:  J Neurooncol       Date:  2011-01-30       Impact factor: 4.130

Review 7.  RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.

Authors:  Eunice L Lozada-Delgado; Nilmary Grafals-Ruiz; Pablo E Vivas-Mejía
Journal:  Life Sci       Date:  2017-08-31       Impact factor: 5.037

8.  Transcriptional profiling of dividing tumor cells detects intratumor heterogeneity linked to cell proliferation in a brain tumor model.

Authors:  Berwini B Endaya; Paula Y P Lam; Adrian C B Meedeniya; Jiri Neuzil
Journal:  Mol Oncol       Date:  2015-09-10       Impact factor: 6.603

Review 9.  Glutamate and tumor-associated epilepsy: glial cell dysfunction in the peritumoral environment.

Authors:  Susan C Buckingham; Stefanie Robel
Journal:  Neurochem Int       Date:  2013-02-04       Impact factor: 3.921

10.  Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures.

Authors:  Elisa Carra; Federica Barbieri; Daniela Marubbi; Alessandra Pattarozzi; Roberto E Favoni; Tullio Florio; Antonio Daga
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.